1. Li, M, Li, H, Hong, G, et al. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings. BMC Cancer. 2019;19(1):67.
Google Scholar | Crossref | Medline2. Hermans, K, van den Brandt, PA, Loef, C, Jansen, R, Schouten, LJ. Alcohol consumption, cigarette smoking and cancer of unknown primary risk: Results from the Netherlands Cohort study. Int J Cancer. 2021;148(7):1586-1597.
Google Scholar | Crossref | Medline3. Olivier, T, Fernandez, E, Labidi-Galy, I, et al. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm? Cancer Treat Rev. 2021;97:102204.
Google Scholar | Crossref | Medline4. Li, M, Li, H, Hong, G, et al. Identifying primary site of lung-limited cancer of unknown primary based on relative gene expression orderings. BMC Cancer. 2019;19(1):67.
Google Scholar | Crossref | Medline5. Bochtler, T, Kramer, A. Does cancer of unknown primary (CUP) truly exist as a distinct cancer entity? Front Oncol. 2019;9:402.
Google Scholar | Crossref | Medline6. Pauli, C, Bochtler, T, Mileshkin, L, et al. A challenging task: identifying patients with cancer of unknown primary (CUP) according to ESMO guidelines: the CUPISCO trial experience. Oncol. 2021;26(5):e769-e779.
Google Scholar | Crossref7. Losa, F, Iglesias, L, Pane, M, et al. Consensus statement by the spanish society of pathology and the spanish society of medical oncology on the diagnosis and treatment of cancer of unknown primary. Clin Transl Oncol. 2018;20(11):1361-1372.
Google Scholar | Crossref | Medline8. Ohta, S, Cho, Y, Shibata, M, et al. Possibility of molecular targeting therapy for the treatment of cancer of unknown primary origin by analysis of intracellular signaling molecules. Exp Ther Med. 2012;3(3):547-549.
Google Scholar | Crossref | Medline9. Noonan, SA, Patil, T, Gao, D, et al. Baseline and on-treatment characteristics of serum tumor markers in stage IV oncogene-addicted adenocarcinoma of the lung. J Thorac Oncol. 2018;13(1):134-138.
Google Scholar | Crossref | Medline10. Chae, YK, Pan, A, Davis, AA, et al. Recent advances and future strategies for immune-checkpoint inhibition in small-cell lung cancer. Clin Lung Cancer. 2017;18(2):132-140.
Google Scholar | Crossref | Medline11. Bae, SB, Cho, HD, Oh, MH, et al. Expression of programmed death receptor ligand 1 with high tumor-infiltrating lymphocytes is associated with better prognosis in breast cancer. J Breast Cancer. 2016;19(3):242-251.
Google Scholar | Crossref | Medline12. La-Beck, NM, Jean, GW, Huynh, C, Alzghari, SK, Lowe, DB. Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy. 2015;35(10):963-976.
Google Scholar | Crossref | Medline13. Schalper, KA, Velcheti, V, Carvajal, D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773-2782.
Google Scholar | Crossref | Medline14. Wolchok, JD, Chan, TA. Cancer: antitumour immunity gets a boost. Nature. 2014;515(7528):496-498.
Google Scholar | Crossref | Medline15. Errico, A . Melanoma: checkMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab. Nat Rev Clin Oncol. 2015;12(8):435.
Google Scholar | Crossref | Medline16. Maine, CJ, Aziz, NH, Chatterjee, J, et al. Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer. Cancer Immunol Immunother. 2014;63(3):215-224.
Google Scholar | Crossref | Medline | ISI17. Homet, MB, Ribas, A. Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. Br J Cancer. 2015;112(9):1421-1427.
Google Scholar | Crossref | Medline18. He, J, Hu, Y, Hu, M, Li, B. Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep. 2015;5:13110.
Google Scholar | Crossref | Medline19. Gettinger, S, Herbst, RS. B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction. Cancer J. 2014;20(4):281-289.
Google Scholar | Crossref | Medline20. Hellmann, MD, Ciuleanu, TE, Pluzanski, A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093-2104.
Google Scholar | Crossref | Medline21. Dong, ZY, Zhong, WZ, Zhang, XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012-3024.
Google Scholar | Crossref | Medline22. Chae, YK, Saleem, N, Roh, Y, et al. Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review. BMC Cancer. 2019;19(1):748.
Google Scholar | Crossref | Medline23. Bloom, BC, Augustyn, A, Pezzi, TA, et al. Rescue of immunotherapy-refractory metastatic merkel cell carcinoma with conventionally fractionated radiotherapy and concurrent pembrolizumab. Front Oncol. 2019;9:223.
Google Scholar | Crossref | Medline24. Lin, X, Lu, T, Xie, Z, et al. Extracranial abscopal effect induced by combining immunotherapy with brain radiotherapy in a patient with lung adenocarcinoma: A case report and literature review. Thorac Cancer. 2019;10(5):1272-1275.
Google Scholar | Crossref | Medline25. Rodel, F, Frey, B, Multhoff, G, Gaipl, U. Contribution of the immune system to bystander and non-targeted effects of ionizing radiation. Cancer Lett. 2015;356(1):105-113.
Google Scholar | Crossref | Medline26. Schoenfeld, JD, Nishino, M, Severgnini, M, et al. Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer. 2019;7(1):112.
Google Scholar | Crossref | Medline27. Dagoglu, N, Karaman, S, Caglar, HB, Oral, EN. Abscopal effect of radiotherapy in the immunotherapy era: systematic review of reported cases. Cureus. 2019;11(2):e4103.
Google Scholar | Medline